Wang Jingbo, Shen Xuemin, Ma Qifan, Yang Lin, Zhou Xiaoyu, Wang Luting, Cui Junqi, Zhang Chunye, Li Guojun, Gross Neil, Li Siyi, Huang Ruimin, Zhan Changyou, Cheng Zhen, Wang Kun, Tian Jie, Yuan Ying, Tao Xiaofeng
Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Department of Oral Mucosal Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai 200011, China.
Cell Rep Med. 2025 Mar 18;6(3):101978. doi: 10.1016/j.xcrm.2025.101978. Epub 2025 Feb 24.
Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.
准确检测口腔潜在恶性疾病（OPMDs）中的恶性转化对于指导有效治疗和改善患者管理至关重要。本研究评估了间充质-上皮转化因子（MET）靶向近红外荧光成像（NIRFI）探针MET结合肽-吲哚菁绿（cMBP-ICG）在OPMDs活检部位选择中的潜力。临床前结果表明，在检测高级别发育异常（HGD）或鳞状细胞癌（SCC）以及降低漏检率方面，NIRFI辅助活检优于基于传统口腔检查（COE）的活检。在一项针对50名患者的临床试验中，与基于COE的活检相比，NIRFI辅助活检的诊断准确性显著更高（91%对72%，p = 0.0005）。这些发现强调了NIRFI在提高诊断精度、支持早期检测以及为OPMDs患者实现及时准确的治疗干预方面的重要性。该临床试验已在注册号ChiCTR2300074454下注册。
